Jupiter Neurosciences (JUNS) Amortizatization of Intangibles (2023 - 2024)
Jupiter Neurosciences (JUNS) posted quarterly Amortizatization of Intangibles of $28275.0 for Q4 2024, up 460.9% year-over-year from $5041.0 in Q1 2024, and up 461.01% quarter-over-quarter from $5040.0 in Q3 2024.
Jupiter Neurosciences (JUNS) Amortizatization of Intangibles (2023 - 2024) Analysis & Trends
Jupiter Neurosciences (JUNS) has reported Amortizatization of Intangibles for 2 consecutive years, with $28275.0 the latest figure, recorded in Q4 2024.
- In Q4 2024, Amortizatization of Intangibles rose 460.9% year-over-year to $28275.0; the TTM figure through Dec 2024 stood at $43288.0 (changed N/A YoY), while the FY2024 annual figure was $43288.0, up 159.02% from the prior year.
- Amortizatization of Intangibles climbed to $28275.0 in Q4 2024 per JUNS's latest filing, from $5040.0 in the prior quarter.
- Across five years, Amortizatization of Intangibles topped out at $28275.0 in Q4 2024 and bottomed at $4986.0 in Q1 2024.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Amortizatization of Intangibles (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn | - |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn | - |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn | - |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn | - |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn | - |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn | - |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn | - |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn | 678,000.00 |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - | - |
| 10 | Jupiter Neurosciences | 3.37 Mn | 1.85 Mn | 21,064.00 | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2024 | 28,275.00 |
| Dec 31, 2024 | 28,275.00 |
| Sep 30, 2024 | 5,040.00 |
| Sep 30, 2024 | 5,040.00 |
| Jun 30, 2024 | 4,987.00 |
| Jun 30, 2024 | 4,987.00 |
| Mar 31, 2024 | 4,986.00 |
| Mar 31, 2024 | 4,986.00 |
| Dec 31, 2023 | 5,041.00 |
| Dec 31, 2023 | 5,041.00 |